Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

This is an interventional treatment trial for Breast Cancer focused on measuring breast cancer, CDK4/6 inhibitor, endocrine therapy, hormone receptor-positive, dalpiciclib, letrozole Read More

Inclusion Criteria： Postmenopausal, premenopausal or perimenopausal women aged ≥18. Postmenopausal was defined as: 1) received bilateral oophorectomy, or aged ≥60; 2) aged <60, reached natural menopause (defined as no menses for 12 or more consecutive months with no other reason for the amenorrhea), and with postmenopausal E2 and FSH level; 3) premenopausal or perimenopausal women may also be enrolled as long as they are willing to receive LHRH agonist therapy during the study； Operable patients with ER+ (>10%), HER2- invasive breast carcinomas, regardless of PR level. HER2- was defined as IHC score of 0+, or IHC score of 2+ with negative ISH (amplification ratio <2.0) according to 2018 ASCO-CAP guideline； Untreated patients with stage IIB-III according to AJCC criteria (8th edition)； Without known hypersensitivity to the study drug or its excipients； A ECOG PS score of 0-1； With the ability to swallow the study drug； With sufficient organ function, including 1) bone marrow function: ANC ≥ 1.5 x 109/L (without growth factors within 14 days); PLT ≥ 100 x 109/L (without corrective therapy within 7 days); Hb ≥ 100 g/L (without corrective therapy within 7 days); 2）liver and kidney function: TBIL ≤ ULN; ALT and AST ≤ 3 × ULN (ALT and AST ≤ 5 × ULN for those with liver metastases); BUN and Cr ≤ 1.5×ULN, and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula); 3) QT interval ≤ 480 ms from the 12-lead electrocardiogram； Able to undergo all puncture biopsies required by the protocol； Volunteered to participate in this study; signed informed consent; with good compliance and willingness to follow-up；

Exclusion Criteria： Previously treated patients, including chemotherapy, radiotherapy, targeted therapy or endocrine therapy, etc.； Concurrently receiving any anti-tumor treatments other than that prescribed by the protocol； Patients with bilateral breast cancer, inflammatory breast cancer or occult breast cancer； Patients with stage IV breast cancer； Patients with severe liver, kidney, or heart dysfunction； Inability to swallow, with chronic diarrhea, with intestinal obstruction, or with other factors affecting drug administration and absorption； Participated in other clinical trials within 4 weeks before enrollment； Known hypersensitivity to the study drug or its excipients; history of ；immunodeficiency, including HIV positive, HCV positive, active viral hepatitis B, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation； History of any cardiac disease, including: 1) arrhythmias requiring drug treatment or of clinical significance; 2) myocardial infarction; 3) heart failure; 4) any other cardiac disease to be inappropriate for this trial judged by the investigator； Women who are pregnant or breastfeeding, women of childbearing potential who test positive for pregnancy test at baseline, or women of childbearing potential who are unwilling to use effective contraception during the study； With serious concomitant disease that endanger safety, or interferes with the ability to complete the study judged by the investigator (including, but not limited to, uncontrolled hypertension, severe diabetes, active infection, etc.)； History of neurological or psychiatric disorders, including epilepsy or dementia; or any other condition inappropriate for this study deemed by the investigator.